Nanotop (Human Serum Albumin)

Human serum albumin increases plasma oncotic pressure, which helps retain water inside blood vessels, thereby expanding circulating volume. It also serves as a carrier protein, binding hormones, fatty acids, and certain drugs, supporting their transport and distribution.

The dose of Nanotop is individualized by the prescribing clinician based on the patient’s albumin level, clinical condition, and desired volume expansion. Exact dosing regimens are determined at the point of care.

Safety data for human serum albumin in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs any theoretical risk, and it should be prescribed by a qualified healthcare professional.

To order Nanotop, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nanotop (human serum albumin) is a natural plasma protein, offering oncotic pressure support without the risk of electrolyte imbalance seen with crystalloid solutions. Compared with synthetic colloids, it has a well‑characterized safety profile and lower incidence of coagulopathy, though cost and availability may differ.

Nanotop should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any product that appears discolored or contains particles.

Nanotop is given by subcutaneous injection using aseptic technique. The injection site should be rotated, and the volume administered per site should follow the prescriber’s instructions to minimize local reactions.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, and rare thromboembolic events. Patients should be monitored closely for signs of hypersensitivity, respiratory distress, or sudden cardiovascular changes during and after administration.

Nanotop is contraindicated in individuals with known hypersensitivity to human serum albumin or any component of the formulation. Caution is advised in patients with severe heart failure, uncontrolled hypertension, or active pulmonary edema, where additional volume may be harmful.